Christopher Ryan Sullivan - 28 Mar 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: AVTX
Reported as of: 28 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2026, 16:10:35 UTC
Prior SEC filing: 02 Mar 2026
Next SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Sullivan, Attorney-in-Fact

Key filing fact

Christopher Ryan Sullivan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 31 Mar 2026.

Key facts

This page summarizes Christopher Ryan Sullivan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Mar 2026, 16:10.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001810417 Primary reporting owner

Sullivan Christopher Ryan

Relationship: Chief Financial Officer
Address: C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature: /s/ Christopher Sullivan, Attorney-in-Fact
Signature date: 31 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +24,200
Change %: +140%
Price
Shares after: 41,538
Date: 28 Mar 2026
Ownership: Direct
Footnotes: F1

AVTX transaction

Common Stock

Tax liability

Transaction value
Shares: -8,241
Change %: -20%
Price: $13.89^*
Shares after: 33,297
Date: 28 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -24,200
Change %: -50%
Price: $0.000000^*
Shares after: 24,200
Date: 28 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,200
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.